Literature DB >> 6958336

A multivariate analysis of prognostic factors in chronic myeloid leukemia.

F Cervantes, C Rozman.   

Abstract

The prognostic value of different clinical and laboratory findings at diagnosis of chronic myeloid leukemia (CML) was analyzed in a series of 121 cytogenetically studied patients. From the univariate and multivariate analysis of the whole series it was apparent that the minority of Ph1-negative patients (11.5%) could be considered as a poor prognosis group. The analysis was then restricted to the Ph1-positive patients. From a multivariate survival analysis (Cox's regression model) of the latter group the following poor prognosis factors emerged: splenomegaly, hepatomegaly, presence of erythroid precursors in peripheral blood, and bone marrow myeloblasts over 5%. From the contribution of each one of these factors to the regression model, a clinical staging of Ph1-positive CML was derived: stage I (low risk, 32% of patients), including patients with one or no factors; stage II (intermediate risk, 38%), including cases with two factors; and stage III (high risk, 30%), including patients with three or four factors. The difference in survival of the patients at different stages was highly significant (p less than 0.001).

Entities:  

Mesh:

Year:  1982        PMID: 6958336

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Prognostic implications of bone marrow features in chronic myelogenous leukaemia.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.

Authors:  J Thiele; H M Kvasnicka; B R Titius; U Parpert; R Nebel; R Zankovich; D Dienemann; H Stein; V Diehl; R Fischer
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

3.  Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.

Authors:  Francisco Cervantes; Pilar López-Garrido; María-Isabel Montero; Fermín Jonte; Jesús Martínez; Juan-Carlos Hernández-Boluda; María Calbacho; Anna Sureda; Gloria Pérez-Rus; José B Nieto; Cristina Pérez-López; José Román-Gómez; Marcos González; Arturo Pereira; Dolors Colomer
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

4.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

5.  Prognostic features at diagnosis of chronic myeloid leukaemia with special emphasis on histological parameters.

Authors:  J Thiele; C Thienel; R Zankovich; R Fischer
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

6.  A study of the myeloid differentiation antigens of the peripheral blood neutrophil granulocytes in the different evolutive phases of chronic myeloid leukemia.

Authors:  M Rozman; F Cervantes; C Rozman
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

Review 7.  Liver in systemic disease.

Authors:  Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

8.  Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India.

Authors:  Lakshmaiah Chinnagiriyappa Kuntegowdanahalli; Govind Babu Kanakasetty; Aditi Harsh Thanky; Lokanatha Dasappa; Linu Abraham Jacob; Suresh Babu Mallekavu; Rajeev Krishnappa Lakkavalli; Lokesh N Kadabur; Rudresha Antapura Haleshappa
Journal:  Ecancermedicalscience       Date:  2016-10-06

9.  Hepatic manifestations in hematological disorders.

Authors:  Jun Murakami; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2013-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.